Ndonovo Therapeutics Inc (ENDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2 | 0 | 33 | 11 | 0 |
| Receivables | N/A | N/A | N/A | 3 | N/A |
| TOTAL | $20 | $36 | $73 | $95 | $16 |
| Non-Current Assets | |||||
| Intangibles | 619 | 780 | 942 | 1,104 | 1,265 |
| TOTAL | $619 | $780 | $942 | $1,104 | $1,265 |
| Total Assets | $638 | $816 | $1,015 | $1,199 | $1,281 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,083 | 1,460 | 1,449 | 879 | 884 |
| Accrued Expenses | 4,757 | 4,417 | 4,134 | 3,832 | 3,543 |
| Other current liabilities | 11,754 | 10,762 | 10,526 | 13,876 | 21,802 |
| TOTAL | $24,666 | $23,696 | $23,137 | $25,488 | $33,382 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 80 | 80 | 80 | 80 | 80 |
| TOTAL | $80 | $80 | $80 | $80 | $80 |
| Total Liabilities | $24,746 | $23,776 | $23,217 | $25,568 | $33,462 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 318,752 | 318,752 | 317,902 | 281,635 | 270,285 |
| Common Shares | 33 | 28 | 28 | 27 | 21 |
| Retained earnings | -68,234 | -66,631 | -65,864 | -67,928 | -75,119 |
| Other shareholders' equity | -2 | -2 | -2 | -2 | -2 |
| TOTAL | $-24,108 | $-22,960 | $-22,202 | $-24,369 | $-32,180 |
| Total Liabilities And Equity | $638 | $816 | $1,015 | $1,199 | $1,281 |